Shots:

• The US FDA has approved Keytryda + CT- with/out bevacizumab- for the treatment of patients with persistent- recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test
• The approval is based on the P-III KEYNOTE-826 trial that demonstrated superior OS and PFS- ORR (68% vs 50%)- mDOR (18.0 vs 10.4mos.)
• The approval marks the first anti-PD-1 combination approved as a 1L treatment for the targeted patients. Additionally- the FDA converted the accelerated approval of Keytruda as a single agent for recurrent or metastatic cervical cancer to a regular approval based on data from KEYNOTE-826 study

 Ref: Businesswire | Image: Merck